Daglyfy

Daglyfy combines sitagliptin and dapagliflozin for oral use, offering a dual-action approach to managing type 2 diabetes. This medication supports blood sugar control and may improve glycemic management.

Daglyfy is primarily used to manage type 2 diabetes in adults. It works by enhancing insulin secretion and reducing glucose production in the liver. This combination therapy is often prescribed for individuals who require additional glycemic control beyond diet and exercise alone.

Common effects of Daglyfy may include urinary tract infections, hypoglycemia, and gastrointestinal discomfort. Some users may experience increased urination or mild dizziness. These effects vary and are not experienced by everyone.

Daglyfy should be used with caution in individuals with kidney issues or a history of pancreatitis. It is important to stay hydrated while taking this medication. Always consult a healthcare provider before starting any new medication.

Daglyfy may interact with certain medications, including insulin and other diabetes drugs. Alcohol consumption should be moderated, as it can affect blood sugar levels. Always inform your healthcare provider about all medications you are taking.